This Week in Startups
Next Unicorns: Developing drugs to extend dog lifespans with Loyal CEO Celine Halioua | E1799
Aug 30, 2023
Celine Halioua, CEO and founder of Loyal, explores groundbreaking ways to extend dog lifespans through innovative drug developments. With her background in neuroscience, she discusses the benefits of canine-specific medications and the parallels between dog and human aging. The episode delves into the challenges of developing effective treatments while addressing genetic issues stemming from selective breeding. Celine also shares insights on the ethics of veterinary research and the critical role of continued advancements in pet health for overall well-being.
01:05:15
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Studying dogs as a model for life extension research can yield valuable insights into improving human health and lifespan, as dogs share similar age-related diseases with humans.
- Loyal, a biotech startup, aims to develop life extension treatments for dogs by taking advantage of the potential market and revenue generated by dog medications, presenting a loyal customer base for life extension treatments.
Deep dives
Using Dogs as a Translational Model for Life Extension
The podcast episode explores the use of dogs as a model for life extension research. By studying the genetics, environment, and diseases found in dogs, researchers can gain valuable insights into improving human health and lifespan. Dogs share similar age-related diseases with humans, such as cancer, osteoarthritis, and dementia, making them a suitable model for testing potential life extension drugs. Additionally, FDA approval for life extension drugs in dogs is more affordable and faster, making it an efficient pathway for research and development.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
